BiomeBank is a clinical stage biotechnology company with a mission to treat and prevent disease by restoring gut microbial ecology.

BiomeBank is on a mission to discover and develop new microbiome-based therapies that will treat a number of chronic diseases with unmet medical need.

In partnership with world-leading organisations running large-phased clinical studies, BiomeBank is building a pipeline of microbiome-based therapies to treat diseases ranging from recurrent clostridioides difficile infection (C.difficile), to Ulcerative Colitis and Crohn’s disease.

The BiomeBank team of translational microbiome experts have developed a unique platform which combines the capabilities of machine learning and microbiology to inform microbiome drug discovery and development.

BiomeBank currently supplies a donor derived microbiome-based therapy used by doctors and hospitals to treat recurrent C.difficile infection.